Overall rank by patents
#24,873
Across all tracked assignees
USPTO PatentsView assignee record - 11 granted patents across 5 technology areas, active 2022–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR).
The verdict
Nuwellis holds 11 US patents across 5 technology areas, rank #24,873 of 50,000 tracked assignees.
Nuwellis, Inc. has been granted 11 US utility patents between 2022 and 2025, placing Nuwellis, Inc. at rank #24,873 across all assignees tracked by PlainPatent. This portfolio spans 5 distinct Cooperative Patent Classification (CPC) subclasses, averaging 18.7 claims per patent with primary concentration in A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR). As a US Corporation, Nuwellis, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Nuwellis sits between Novita Pharmaceuticals, Inc. (11 patents, rank #24,869) and Nanoholdings, Llc (11 patents, rank #24,877) - the closest US assignees by grant volume. The composite Innovation Score of 47.7/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2022 through 2025, with 11 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Nuwellis, Inc.'s 18.7 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 5 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Nuwellis, Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
NOVITA PHARMACEUTICALS, INC.
11 patents
NSV Group FZCO
11 patents
NUORGANICS LLC
11 patents
NUTRITION & BIOSCIENCES USA 1, LLC
11 patents
NXGN Data, Inc.
11 patents
NYMI INC.
11 patents
Naiad Maritime Group, Inc.
11 patents
Nanoholdings, LLC
11 patents
NUWELLIS, INC.
11 patents
What this shows Nuwellis holds 11 patents at rank #24,873, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Nuwellis's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
48 Top 18% higher than 82% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2022 | 1 | 9.1% |
| 2023 | 3 | 27.3% |
| 2024 | 4 | 36.4% |
| 2025 | 3 | 27.3% |
Top 5 of 5 technology areas
Overall rank by patents
#24,873
Across all tracked assignees
47.7 out of 100
How to use this portfolio
Nuwellis's 11 grants land it in the top 18% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.